Marco P A W Claasen
Overview
Explore the profile of Marco P A W Claasen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gravely A, Claasen M, Ivanics T, Winter E, Peralta P, Selzner M, et al.
Clin Transplant
. 2025 Jan;
39(2):e70086.
PMID: 39869426
Background: Low post-operative day (POD) 1 Factor V has been retrospectively associated with graft loss after liver transplantation when stratified by a cutoff of 0.36 U/mL. We aimed to validate...
2.
Yan M, Li Z, Claasen M, Santiago A, Rajendran L, Munoz-Schuffenegger P, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):1771-1783.
PMID: 39692983
Introduction: Patients with advanced hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) are recommended to receive systemic therapy according to guidelines. Stereotactic body radiotherapy (SBRT) and surgery are increasingly used in...
3.
Magyar C, Rajendran L, Babakhani S, Choi W, Li Z, Bucur R, et al.
Surgery
. 2024 Dec;
178():108924.
PMID: 39632224
Background: Postoperative acute kidney injury is associated with an increase in hospital length of stay and mortality. Intraoperative hemodynamics and fluid management may contribute to acute kidney injury. The aim...
4.
Yan M, Li Z, Claasen M, Santiago A, Rajendran L, Munoz-Schuffenegger P, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):1841-1842.
PMID: 39627643
No abstract available.
5.
Magyar C, Li Z, Aceituno L, Claasen M, Ivanics T, Choi W, et al.
Am J Transplant
. 2024 Aug;
25(2):406-416.
PMID: 39163907
Living donor liver transplantation (LDLT) is a curative treatment for various liver diseases, reducing waitlist times and associated mortality. We aimed to assess the overall survival (OS), identify predictors for...
6.
Li Z, Jones O, Magyar C, Claasen M, Ivanics T, Choi W, et al.
Ann Surg
. 2024 Jul;
PMID: 39041223
Objective: Assess the impact of having a living donor on waitlist outcomes and overall survival through an intention-to-treat analysis. Background: Living-donor liver transplantation (LDLT) offers an alternative to deceased donation...
7.
Jones O, Claasen M, Ivanics T, Choi W, Gavaria F, Rajendran L, et al.
Liver Transpl
. 2024 Apr;
30(8):785-795.
PMID: 38619393
Living donor liver transplantation (LDLT) offers the opportunity to decrease waitlist time and mortality for patients with autoimmune liver disease (AILD), autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis....
8.
Choi W, Babakhani S, Claasen M, Castelo M, Bucur R, Gaviria F, et al.
Surgery
. 2023 Oct;
174(6):1393-1400.
PMID: 37863687
Background: The global benchmark cut-offs were set for laparoscopic liver resection procedures: left lateral sectionectomy, left hepatectomy, and right hepatectomy. We aimed to compare the performance of our North American...
9.
Ivanics T, Claasen M, Samstein B, Emond J, Fox A, Pomfret E, et al.
Ann Surg
. 2023 Jul;
279(1):104-111.
PMID: 37522174
Objective: To evaluate long-term oncologic outcomes of patients post-living donor liver transplantation (LDLT) within and outside standard transplantation selection criteria and the added value of the incorporation of the New...
10.
Claasen M, Ivanics T, Beumer B, de Wilde R, Polak W, Sapisochin G, et al.
JHEP Rep
. 2023 May;
5(6):100745.
PMID: 37234277
Background & Aims: Management of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is not well-defined. Therefore, we evaluated the management of cHCC-CCA using an online hospital-wide multicentre survey sent to expert centres. Methods: A...